Transgenomic (TBIO) Tops Q4 EPS by 13c

Transgenomic (NASDAQ: TBIO) reported Q4 EPS of ($0.28), $0.13 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $9.5 million versus the consensus estimate of $7.2 million.

For earnings history and earnings-related data on Transgenomic (TBIO) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c
• Inhibrx, Inc. (INBX) Misses Q2 EPS by 54c